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A B S T R A C T
The KEAP1-Nrf2-ARE antioxidant system is a principal means by which cells respond to oxidative and
xenobiotic stresses. Sulforaphane (SFN), an electrophilic isothiocyanate derived from cruciferous vegetables,
activates the KEAP1-Nrf2-ARE pathway and has become a molecule-of-interest in the treatment of diseases in
which chronic oxidative stress plays a major etiological role. We demonstrate here that the mitochondria of
cultured, human retinal pigment epithelial (RPE-1) cells treated with SFN undergo hyperfusion that is
independent of both Nrf2 and its cytoplasmic inhibitor KEAP1. Mitochondrial fusion has been reported to be
cytoprotective by inhibiting pore formation in mitochondria during apoptosis, and consistent with this, we show
Nrf2-independent, cytoprotection of SFN-treated cells exposed to the apoptosis-inducer, staurosporine.
Mechanistically, SFN mitigates the recruitment and/or retention of the soluble ﬁssion factor Drp1 to
mitochondria and to peroxisomes but does not aﬀect overall Drp1 abundance. These data demonstrate that
the beneﬁcial properties of SFN extend beyond activation of the KEAP1-Nrf2-ARE system and warrant further
interrogation given the current use of this agent in multiple clinical trials.
1. Introduction
Sulforaphane (SFN) is an isothiocyanate compound derived in the
diet most commonly from cruciferous vegetables [56]. It is generated in
plants as a xenobiotic response to predation via vesicular release of the
hydrolytic enzyme myrosinase from damaged cells; this enzyme con-
verts glucosinolates to isothiocyantes [42]. Over the last two decades,
SFN has been extensively characterized for its reported anticancer,
antioxidant, and antimicrobial properties [57]. Much of this eﬃcacy
has been attributed to the capacity of SFN to modulate the KEAP1-
Nrf2-antioxidant response element (ARE) signaling pathway, although
additional activities of the compound have been identiﬁed, including
the inhibition of histone deacetylase activity and cell cycle progression
[29]. Nrf2 is the master antioxidant transcription factor and under
conditions of homeostasis, its stability is suppressed through the action
of the cytoplasmic Cullin3KEAP1 ubiquitin ligase complex [20].
Speciﬁcally, Nrf2 is recruited to the Cullin3KEAP1 ligase by binding to
the dimeric substrate adaptor KEAP1 and is subsequently modiﬁed
with polyUb chains that target the transcription factor for proteasome-
mediated degradation. This constitutive turnover limits the half-life of
Nrf2 in unstressed cells to ~15 min [30,33,46,55]. In response to
numerous types of stress, most notably oxidative stress, KEAP1, a
cysteine-rich protein, acts as a redox sensor, and oxidative modiﬁcation
of critical cysteines, particularly C151, of KEAP1 dissociates Nrf2-
KEAP1 from CUL3 thereby preventing Nrf2 degradation [20,55,8].
Notably, SFN, and possibly other Nrf2 activators, mimic oxidative
stress by modifying C151 of KEAP1 e.g. [21]. Stabilization of Nrf2
allows for its translocation to the nucleus where it induces the
expression of a battery of Phase II antioxidant and detoxiﬁcation
genes. Nrf2 binds to the antioxidant response promoter elements
(ARE) of its cognate target genes through heterodimerization with
small Maf proteins [19]. This system presents a dynamic and sensitive
response to indirect antioxidants like SFN, free radicals generated by
the mitochondria [16], or other physiologic sources of oxidative stress
[41].
Mitochondria are dynamic, subcellular organelles that regulate a
host of cellular functions ranging from ATP production and intracel-
lular calcium buﬀering to redox regulation and apoptosis [13,49].
Mitochondria also represent the principal source of reactive oxygen
species (ROS) within the cell. Proper regulation of mitochondrial
function is therefore necessary for optimizing ATP production to meet
cellular needs while simultaneously minimizing the potentially harmful
eﬀects of excessive free radical production. A critical requirement for
ﬁne modulation of mitochondrial function is the capacity for mito-
chondria to function both independently as biochemical machines and
as part of a vast, responsive network.
Mitochondrial network morphology and function are determined by
a regulated balance between ﬁssion and fusion. Mitochondrial ﬁssion is
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required for daughter cell inheritance of mitochondria during cell
division [28] as well as for the selective, autophagic degradation of
depolarized or damaged mitochondria, termed mitophagy [1].
Conversely, fusion is required for complementation of mitochondrial
genomes and sharing of electron transport chain components between
neighboring mitochondria [54]. At the molecular level, mitochondrial
ﬁssion and fusion are regulated by large, dynamin-like GTPases. Three
enzymes primarily regulate fusion: Mitofusins 1 and 2 (Mfn1/2) are
two-pass outer membrane proteins that mediate outer membrane
fusion via heterotypic interactions between adjacent mitochondria
[15,25,37], while OPA1 is an inner membrane protein that simulta-
neously ensures matrix connectivity by regulating the melding of inner
membranes [5]. The GTPase activity of all three proteins is required for
robust fusion [18,5], and OPA1 is further regulated by complex
proteolysis within the mitochondrial inner membrane by the proteases
OMA1 [14], PARL [6], and YME1L [45]. Importantly, intact mitochon-
drial membrane potential is required for eﬃcient fusion in order to
suppress integration of damaged and healthy mitochondria [26].
Mitochondrial ﬁssion is primarily catalyzed by a cytosolic protein
called Dynamin-related protein 1 (Drp1/DNM1L). Drp1 is recruited
from the cytosol to prospective sites of ﬁssion on the mitochondrial
outer membrane [43]. The major receptors for Drp1 on the outer
membrane are mitochondrial ﬁssion factor (Mﬀ) [32] and, to a lesser
extent, Fission 1 (Fis1) [51]. Additionally, a decoy receptor, MIEF1/
MiD51, was discovered that acts to further limit the activity of Drp1
protein at potential ﬁssion sites [58]. Once docked at the mitochondrial
outer membrane, Drp1 oligomerizes into spiral-like structures around
the body of the mitochondrion and then utilizes the energy derived
from GTP hydrolysis to mediate the physical scission of the mitochon-
drial outer and inner membranes [17]. Endoplasmic reticulum-derived
tubules act as an initial constrictor of mitochondria prior to Drp1
oligomerization, underscoring the revelation that non-constricted
mitochondria are wider than the permissive circumference of a
completed Drp1 spiral [12]. Actin dynamics are also important for
the ER-mitochondria interactions that precede mitochondrial ﬁssion
[24]. In addition to its role in mitochondrial ﬁssion, Drp1 catalyzes the
ﬁssion of peroxisomes [40].
Drp1 is very similar to the well-characterized dynamin protein in
that both proteins contain an N-terminal GTPase domain, a Middle
domain that is critical for self-oligomerization, and a C-terminal
GTPase eﬀector domain [31]. Drp1 achieves selectivity for mitochon-
drial membranes through a combination of interactions with its
receptor proteins Mﬀ and Fis1 and also through its aﬃnity for the
mitochondria-speciﬁc phospholipid cardiolipin via the unique B-insert
domain of Drp1 [2]. Drp1 typically exists as a homotetramer in the
cytoplasm, and higher order assembly at mitochondrial ﬁssion sites is
mediated by the Middle domain of Drp1 [3].
Given the implicit link between mitochondrial function and the
KEAP1-Nrf2-ARE pathway, we investigated the eﬀects of Nrf2 activa-
tion on mitochondrial structure and function. We demonstrate here
that SFN induces mitochondrial hyperfusion that, unexpectedly, is
independent of both Nrf2 and KEAP1. This eﬀect of SFN is through an
inhibition of Drp1 function. We further demonstrate that SFN confers
resistance to apoptosis that is Nrf2-independent and mimics that
observed in cells depleted of Drp1. These data collectively indicate
that in addition to stabilizing and activating Nrf2, SFN modulates
mitochondrial dynamics and preserves cellular ﬁtness and survival.
2. Results
2.1. Sulforaphane induces Nrf2/KEAP1-independent hyperfusion of
mitochondria
In the course of studying the eﬀects of Nrf2 activation on
mitochondrial network dynamics, we discovered that treatment of
immortalized, human retinal pigment epithelial (RPE-1) cells with
sulforaphane (SFN), a potent activator of Nrf2 signaling, induced a
robust fusion of the mitochondrial network when compared with
vehicle-treated control cells (Fig. 1A and B). The morphology of the
mitochondria in these cells greatly resembled that of the mitochondria
in cells depleted by siRNA of endogenous Drp1, the principal mito-
chondrial ﬁssion factor (Fig. 1A). This result raised the intriguing idea
that mitochondrial ﬁssion and fusion status responds directly to Nrf2
levels in the cell. However, stimulation of cells with other Nrf2
stabilizers and activators such as the proteasome inhibitor MG132,
the pro-oxidant tBHQ, or knockdown of the Nrf2 inhibitor KEAP1 did
not induce mitochondrial fusion (Fig. 1A and B). Stabilization of Nrf2
by these manipulations was conﬁrmed by western blotting for endo-
genous Nrf2 (Fig. 1C). Furthermore, expression of Nrf2 was dispen-
sable for SFN-induced mitochondrial fusion, as knockdown of endo-
genous Nrf2 with siRNA failed to counter this phenotype (Fig. 1D–F).
Because SFN stimulates the KEAP1-Nrf2-ARE pathway by covalently
modifying cysteine residues of KEAP1 [21], we knocked down KEAP1
to address whether SFN-induced mitochondrial hyperfusion is stimu-
lated through a KEAP1-dependent, but Nrf2 independent pathway.
However, depletion of KEAP1 also failed to abrogate SFN-induced
mitochondrial fusion (Fig. 1G–I). In fact, SFN reversed the pro-ﬁssion
morphology induced by depletion of KEAP1 (Fig. 1G, panel b versus
panel d). These results indicate that SFN treatment causes mitochon-
drial fusion independent of the canonical KEAP1-Nrf2-ARE pathway
and led us to interrogate whether SFN directly aﬀects components of
the mitochondrial ﬁssion or fusion machinery.
2.2. Sulforaphane impairs the mitochondrial association of Drp1
Based on the ﬁnding that SFN-treatment induces mitochondrial
hyperfusion, we reasoned that this phenotype was either a consequence
of excessive fusion activity or an inhibition of ﬁssion activity. To
discriminate between these two possibilities, we compared the mor-
phology of peroxisomes in the presence and absence of SFN.
Peroxisomes are similar to mitochondria in that they are dynamic
organelles the shape and length of which are constantly in ﬂux [44].
Peroxisomes contain both Fis1 and Mﬀ in their outer membrane and,
as a consequence, are targets for Drp1-mediated ﬁssion [22,23].
However, peroxisomes do not utilize the fusion machinery of the
mitochondrial network and consequently, do not undergo fusion
[39]. Rather, peroxisomal ﬁssion is opposed by the lengthening of
existing peroxisomes via de novo addition of membranes and proteins
[44]. Because peroxisomes lack Mfn1/2 and OPA1, we reasoned that if
SFN activates the fusion machinery rather than inhibiting the ﬁssion
machinery, peroxisome length would not be aﬀected. In vehicle-treated
cells, peroxisomes are maintained as short, round, punctiform orga-
nelles (Fig. 2, panels b and d). However, SFN treatment increased
peroxisome length by ~2-fold as compared to control cells (Fig. 2,
panels f and h). Furthermore, many of the peroxisomes were pinched
near the center, indicating a potential scission defect (Fig. 2, panel h,
arrowheads). Likewise, peroxisomes in cells transfected with Drp1
siRNA were abnormally long (Fig. 2, panels j and l), conﬁrming that
Drp1 is required for peroxisomal ﬁssion and suggesting that SFN-
treatment causes mitochondrial and peroxisomal phenotypes by dis-
rupting the ﬁssion machinery.
We next determined how SFN restricts Drp1 function. Possibilities
included reductions in expression levels, recruitment/retention at
mitochondria, oligomerization, or enzymatic activity of the GTPase. A
deﬁcit in any one of these would result in reduced mitochondrial ﬁssion
and hyperfusion. We did not detect reproducible changes in Drp1
protein levels after SFN-treatment (Figs. 1C and 3A), and therefore
concluded that SFN does not alter Drp1 stability or expression,
consistent with Drp1 having a half-life of > 10 h [50] and our SFN
treatments being of shorter duration. Next, we investigated whether
SFN aﬀected the recruitment or retention of Drp1 to mitochondria.
Fractionation studies showed that SFN induced a loss of Drp1 from the
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mitochondrial fraction (Fig. 3A, lanes 7–8 and Fig. 3B). As reported
previously [43], only a minor fraction of Drp1 (~3%) is associated with
the mitochondrial network at any given time during steady state
conditions with most of the enzyme residing in the cytoplasm
(Fig. 3A, lanes 5–8). These fractionation data were conﬁrmed using
co-localization analysis which showed a ~40% reduction in mitochon-
dria-localized, punctate Drp1 foci after SFN-treatment (Fig. 3C and D).
Together, these data indicate that the mitochondrial fusion induced by
SFN is, at least partially, due to the attenuated association of Drp1 with
the mitochondria. Our data do not distinguish between whether SFN
interferes with the mitochondrial recruitment versus the mitochondrial
retention of Drp1, or both, as the analysis of endogenous Drp1 was not
amenable to visualizing the GTPase by live-cell microscopy.
2.3. Sulforaphane confers protection against staurosportine-induced
apoptosis independent of Nrf2
Previous work has shown that mitochondrial ﬁssion is permissive in
Fig. 1. SFN induces Nrf2/KEAP1-independent mitochondrial fusion. (A) RPE-1 cells were transfected with the indicated siRNAs and 3 days later treated with DMSO or the Nrf2
activators SFN (50 μM), MG132 (10 μM), or tBHQ (100 μM) for 4 h. Mitochondria (red) are labeled with an anti-Tom20 antibody, and nuclei (blue) are counterstained with DAPI. (B)
Graph showing quantiﬁcation of mitochondrial morphology scoring from (A). > 50 cells per condition were evaluated in a blinded fashion. (C) Representative western blots from (A). (D)
RPE-1 cells were transfected with 10 nM siRNA and 3 days later treated with SFN for 4 h prior to being ﬁxed and stained as in (A). (E) Graph showing quantiﬁcation of mitochondrial
phenotype scoring from (D). > 100 cells per condition were evaluated in a blinded fashion. (F) Representative western blots from (D). (G) Cells were transfected and treated as in (D)
with siCON or siKEAP1. (H) Cells from (G) were scored as in (B) and (E) on the basis of mitochondrial morphology. (I) Representative western blots from (G). Data in (B), (E), and (H)
were compiled from 3 independent experiments each and statistical signiﬁcance was determined by two-tailed Student's t-test. Error bars reﬂect +/- S.D. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article).
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the formation of pores in the outer mitochondrial membrane generated
by Bax/Bak during apoptosis [11]. Drp1 has been shown to be
selectively recruited to mitochondria during apoptosis [11] and,
consistent with this, fragmented mitochondria have been observed
early in the process [27]. Conversely, inhibiting mitochondrial ﬁssion is
thought to inhibit apoptosis by blocking the formation of the outer
membrane pores that allow for cytochrome c release [53]. Accordingly,
stimulating mitochondrial fusion delays the progression of apoptosis
induced by compounds including staurosporine (STS) [14]. To deter-
mine whether SFN protects RPE-1 cells from STS-mediated apoptosis
and if so, whether this requires Nrf2, we established an assay to readily
induce poly ADP ribose polymerase (PARP) cleavage, a substrate of
activated caspase-3 and deﬁnitive marker of apoptosis. Treatment of
RPE-1 cells with 1 µM STS for 6 h only caused a very modest cleavage
of PARP yet this was prevented by SFN co-treatment (e.g., Fig. 4A, lane
3 versus 4). To increase the robustness of this assay, we further
sensitized cells to STS-induced apoptosis by pre-treating them with
siRNA targeting the anti-apoptotic factor, Bcl-XL. This pretreatment
reduced the expression of Bcl-XL and markedly promoted PARP
cleavage as a function of time exposed to STS (Fig. 4B, compare lane
2 to lanes 4–10). Importantly, 2 h of pre-treatment with SFN mitigated
PARP cleavage in cells exposed to STS (Fig. 4C, lane 3 versus 4 and lane
5 versus 6). Likewise, cells stably depleted of Nrf2 by CRISPR/Cas9
were comparably protected from STS toxicity by SFN pre-treatment
(Fig. 4C, lane 11 versus 12 and lane 13 versus 14 and Fig. 4D). This
protection was observed using both PARP cleavage (Fig. 4C and D) and
cellular morphology (Fig. 4E) as readouts. The eﬃcacy of Nrf2
depletion by CRISPR/Cas9 was conﬁrmed by western blotting
(Fig. 4C, Nrf2 blot). As predicted, depleting cells of Drp1, which also
yields a hyperfusion phenotype (Fig. 1A), also blocked PARP cleavage
in response to STS as compared to control cells incubated with SFN
(Fig. 4F and G). Together, these ﬁndings are consistent with SFN
conferring protection against apoptosis through its capacity to restrict
Drp1 function, independent of the stabilization and activation of Nrf2.
3. Discussion
We have discovered that SFNmodulates mitochondrial ﬁssion/fusion
dynamics independent of its eﬀects on the KEAP1-Nrf2-ARE pathway.
This is intriguing because of an assumed link between mitochondrial
dysfunction and ROS production and the necessity of squelching
mitochondria-derived free radicals through the activation of Nrf2. This
additional functional impact of SFN is of potential importance given the
more than 30 clinical trials currently underway testing SFN for the
treatment of a variety of diseases including prostate cancer, obstructive
pulmonary disease, and sickle cell disease [10,47,7].
Because SFN is an isothiocyanate [56] and it activates Nrf2
signaling by directly acylating critical KEAP1 cysteines to suppress
Nrf2 degradation [21], it follows that SFN exerts its pro-fusion eﬀects
by modulating the activity of a ﬁssion or fusion factor via cysteine
modiﬁcation. Our data strongly support Drp1 being negatively regu-
lated by SFN although whether the GTPase is a direct target of
acylation remains to be elucidated. Despite this knowledge gap, the
function of Drp1 is clearly being compromised by SFN as both
mitochondria and peroxisomes become hyperfused in response to
SFN treatment and these organelles share Drp1 for their respective
scission events [38]. In addition, SFN decreases the amount of Drp1
that localizes and accumulates at mitochondria (Fig. 3). Because our
Fig. 2. SFN induces peroxisomal lengthening. (A) RPE-1 cells were transfected with 10 nM of the indicated siRNA and 3 days later treated with DMSO or 50 μM SFN for 4 h.
Peroxisomes (green) were labeled with an anti-PMP70 antibody, mitochondria with MitoTracker (red), and DNA counterstained with DAPI. Enlarged insets of peroxisomes are shown
on the right (panels d, h, and l) to facilitate visualization of the changes in morphology induced by SFN and Drp1 depletion. Arrowheads highlight constriction points. (For interpretation
of the references to color in this ﬁgure legend, the reader is referred to the web version of this article).
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experiments were done with all endogenous proteins, our detection of
Drp1 at mitochondrial ﬁssion sites is under steady-state conditions,
and consequently, we cannot distinguish between a recruitment versus
a retention defect of the enzyme caused by SFN. Further, we cannot
eliminate the possibility that SFN acylates a receptor at the mitochon-
dria (Fis1 or Mﬀ) to block Drp1 recruitment yet, we suspect that Drp1
is directly modiﬁed. Drp1 has nine cysteines, eight of which reside
within the Middle Domain that is required for oligomerization [3], and
one of which resides in the GTPase Eﬀector Domain (GED) at the C-
terminus of Drp1. Direct acylation of any of these cysteines could cause
an activity defect in Drp1 and therefore underlie the eﬀect of SFN on
mitochondrial dynamics. Notably, prior work suggests that defects in
oligomerization and catalytic activity can abrogate the retention of
Drp1 at the mitochondria [52]. Cys644 in the GED domain is a
particularly attractive target based on previous work showing that
mutation of this cysteine phenocopies mutations that impair Drp1
GTPase activity [4] and that this particular cysteine is modiﬁed by
thiol-reactive electrophiles [9]. Resolution of this outstanding question
will require mass spectrometric validation.
In summary, we have identiﬁed a novel, cytoprotective function for
the clinically-relevant compound SFN. In addition to activating the
master anti-oxidant transcription factor Nrf2, SFN promotes mitochon-
drial and peroxisomal fusion, and this eﬀect is independent of Nrf2. The
mechanism underlying this phenomenon involves a reduction in the
function of the GTPase Drp1, the primary mediator of mitochondrial and
peroxisomal ﬁssion. A major consequence of SFN-mediated mitochon-
drial fusion is that cells become resistant to the toxic eﬀects of the
apoptosis inducer staurosporine. This additional cytoprotective action of
SFN could be of particular clinical utility in the numerous neurodegen-
erative diseases for which age is the leading risk factor (e.g., Parkinson's
Disease, Alzheimer's Disease, Age-related Macular Degeneration) as
these maladies have been associated with apoptosis and reduced levels
and/or dysregulation of Nrf2 [35,36,48]. Together, these data demon-
strate that the cytoprotective properties of SFN extend beyond activation
of the KEAP1-Nrf2-ARE system and warrant further studies given the
current use of this agent in multiple clinical trials.
4. Materials and methods
4.1. Apoptosis assays
Cells were seeded and transfected with siRNA as indicated below.
Fig. 3. SFN causes a loss of Drp1 from the mitochondria. (A) Subcellular fractionation of RPE-1 cells following 4 h of DMSO or SFN. Whole-cell lysates (WCL), nuclear (Nuc), cytosolic
(Cyto), and crude mitochondrial (Mito) fractions were resolved by SDS-PAGE and processed for western blotting with the indicated antibodies. The migration of molecular weight
markers is indicated on the left. (B) Graphs showing densitometric quantiﬁcation of Drp1 in the indicated fractions from (A). (C) RPE-1 cells were transfected with 10 nM siCON or
siDrp1 and 3 days later treated with DMSO or SFN for 4 h. Drp1 (green) was visualized with an anti-Drp1 antibody, mitochondria with MitoTracker (red), and nuclei with DAPI (blue).
(D) Automated co-localization analysis of Drp1 and MitoTracker signal from (C). Data in (B) and (D) were compiled from 3 and 5 independent experiments, respectively, and statistical
signiﬁcance was determined by two-tailed Student's t-test. Error bars reﬂect +/- S.D and asterisks denote statistical signiﬁcance. (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article).
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Fig. 4. The cytoprotective eﬀects of SFN are independent of Nrf2 expression (A) RPE-1 cells were pre-treated with DMSO or 50 μM SFN for 2 h prior to treatment with DMSO, 1 μM
staurosporine (STS), or 50 μM etoposide for 6 h and were processed for anti-PARP western blotting. (B) RPE-1 cells were transfected with 2.5 nM siCON, 1 nM siBcl-XL, or 2.5 nM
siBcl-XL and 3 days later were treated with DMSO or 1 μM STS for 2, 4, or 6 h. Representative western blots are shown and the migration of molecular weight markers is indicated on the
left. (C) CRISPR/Cas9-generated wild-type (Nrf2WT) and Nrf2 knockout (Nrf2KO) RPE-1 cells were transfected with 1 nM siBcl-XL and 3 days later were pre-treated with DMSO or
50 μM SFN for 2 h. Subsequently, the cells were treated with 1 μM STS for 2, 4, or 6 h. Representative western blots with the indicated antibodies are shown. (D) Quantiﬁcation of
cleaved PARP as a percentage of total PARP (cleaved+uncleaved) from 3 independent experiments. Importantly, the levels of cleaved PARP were comparable whether cells expressed
Nrf2 or not, indicating that SFN protection from STS is independent of the transcription factor. (E) 20X phase-contrast images taken immediately prior to harvest of lysates from (C).
Scale bar=65 µm. (F) Representative western blots demonstrating that depletion of Drp1 confers near-comparable protection from STS as SFN treatment. RPE-1 cells were transfected
with 1 nM siBcl-XL and additionally transfected with either 10 nM siCON or 10 nM siDrp1. 3 days later, siCON cells were pre-treated with SFN as in (A) and (C) and then exposed to STS
for 4 h prior to being harvested and processed for western blotting with the indicated antibodies. (G) Same as (D) for the data presented in (F) compiled from 3 independent
experiments. Error bars reﬂect +/- S.E.M.
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The cells were pre-treated with 50 μM sulforaphane for 2 h to induce
mitochondrial fusion and were then treated with 1 μM staurosporine to
induce apoptosis. At the time of harvest, media was collected in
individual tubes and subjected to high speed centrifugation to pellet
apoptotic cells. This cell pellet was combined with adherent cells and
solubilized in 2 times-concentrated Laemmli buﬀer. Samples were
subjected to anti-PARP western blotting.
4.2. CRISPR/Cas9 construct generation
To create LentiCRISPR/eCas9 1.1, LentiCRISPR v2 (addgene
#52961) was ﬁrst cut with Age1 and BamH1. Next, SpCas9 from
eSpCas9 1.1 (addgene #71814) was PCR ampliﬁed with Age1 and
BamH1 overhangs using the following primers (Forward
AGCGCACCGGTTCTAGAGCGCTGCCACCATGGACTATAAGGACCAC-
GAC, Reverse AAGCGCGGATCCCTTTTTCTTTTTTGCCTGGCCGG)
and ligated into the cut vector above. sgRNA sequences were deter-
mined by using Benchling.com. Parameters were set to target the
coding sequence with the highest on-target and lowest oﬀ-target scores.
The following sequences (targeting sequence underlined, hs
sgNFE2L2#1 sense CACCGCGACGGAAAGAGTATGAGC, antisense
AAACGCTCATACTCTTTCCGTCGC; hs sgNFE2L2#2 sense CACCGG-
TTTCTGACTGGATGTGCT, antisense AAACAGCACATCCAGTCAGAA-
ACC; hs sgNFE2L2#3 sense CACCGGAGTAGTTGGCAGATCCAC, anti-
sense AAACGTGGATCTGCCAACTACTCC) were annealed and ligated
into BsmB1 cut LentiCRISPR/eCas9 1.1. Lentivirally infected RPE-1
cells were selected with puromycin and maintained as a pooled
population. Knockout was conﬁrmed by immunoﬂuorescence and
western blotting.
4.3. Cell culture and transfections
Human retinal pigment epithelial cells transformed with telomer-
ase (RPE-1) (ATCC) were cultured in Dulbecco's Modiﬁed Eagle
Medium (DMEM) containing 1 g/L glucose supplemented with peni-
cillin, streptomycin, 1X non-essential amino acid cocktail (Life
Technologies), and 10% Fetal Bovine Serum (Life Technologies). For
siRNA-transfections, 30,000–35,000 cells/mL were seeded overnight.
Cells received 10 nM siRNA diluted in serum-free DMEM and com-
bined with 0.3% Interferin transfection reagent (PolyPlus). For apop-
tosis sensitization, cells received 1 nM Bcl-XL siRNA. Cells were
harvested 2–3 days post-transfection.
4.4. Chemicals, antibodies, and siRNA oligos
Antibodies against α-tubulin (Cell Signaling), β-tubulin (Sigma),
Drp1 (BD Biosciences), KEAP1 (Proteintech), Lamin B1 (Abcam),
PARP (Cell Signaling), PMP70 (Abcam), and Tom20 (BD
Biosciences) were used at 1:1000 dilutions for western blotting and
for immunoﬂuorescence. In-house, anti-Nrf2 rabbit antibody was used
at 1:2000 for western blotting [34,59]. Sulforaphane (Sigma) and
staurosporine (Tocris) were used at 50 μM and 1 μM respectively.
siRNAs against Drp1 (Dharmacon), Nrf2 (Dharmacon), KEAP1 (Cell
Signaling), and Bcl-XL (Cell Signaling) were used at 10 nM unless
otherwise noted.
4.5. Immunoﬂuorescence and in vivo labeling
Cells seeded on 18 mm glass coverslips were treated with vehicle or
drug, ﬁxed in 3.7% formaldehyde and then permeabilized in 0.2%
Triton X-100/PBS on ice for 10 min. Primary antibodies were incu-
bated in 3% bovine serum albumin (BSA) in PBS overnight at 4 °C.
Following PBS washes, cells were incubated for 1 h in species-appro-
priate, Alexa488- or Alexa546-, conjugated secondary antibodies (diluted
1:1000) and 0.1 μg/mL DAPI (Sigma) in 3% BSA/PBS. Mitochondria
were visualized either by anti-Tom20 immunoﬂuorescence or by
incubating cells in 200 nM MitoTracker Red CMXRos (Molecular
Probes, Inc.) in serum-free DMEM for 30 min at 37 °C prior to ﬁxation.
4.6. Microscopy and image analysis
Immunoﬂuorescence samples were viewed on an LSM710 Confocal
microscope (Carl Zeiss). Micrographs were captured using 63X or
100X oil immersion objectives and images adjusted and enhanced
using Adobe Photoshop CS6. Co-localization analysis was performed
using Carl Zeiss LSM710 co-localization feature with thresholds
manually set while blinded to the identity of the samples. Scale bars
throughout, unless otherwise indicated, are 10 µm. Mitochondrial
morphology was assessed by blinded scoring. If the mitochondria of
a cell were maintained as multiple, round, discriminate puncta, the cell
was scored as ‘ﬁssion’. If individual mitochondria were indistinguish-
able and the whole mitochondrial network appeared continuous, the
cell was scored as ‘fusion’. All other cells, including those with
clustering mitochondria, were scored as ‘intermediate’.
4.7. Subcellular fractionations
RPE-1 cells were grown to conﬂuence. Following a PBS wash, cells
were subjected to centrifugation at 600×g for 10 min and resuspended
in 600 μL isolation buﬀer (210 mM Mannitol, 70 mM Sucrose, 5 mM
MOPS, 1 mM EDTA pH 7.4+1 mM PMSF). The suspension was lysed
30 times in a Dounce homogenizer. A fraction of the homogenate was
preserved as a “whole cell lysate.” The remainder was subjected to
centrifugation at 800×g for 10 min to pellet nuclei. Supernatants were
subjected to centrifugation at 1500×g for 10 min to clear remaining
nuclei and unlysed cells. This supernatant was subjected to centrifuga-
tion at 15,000×g for 15 min to pellet mitochondria. The supernatant
was preserved as the “cytosolic fraction”. The pellet was washed gently
with PBS and resuspended in isolation buﬀer. The protein concentra-
tion of each fraction was measured by bicinchoninic acid (BCA) assay
and equivalent amounts of protein were resolved by SDS-PAGE.
4.8. Western blotting
Cells were washed in PBS and solubilized in 2 times concentrated
Laemmli solubilizing buﬀer (100 mM Tris [pH 6.8], 2% SDS, 0.008%
bromophenol blue, 2% 2-mercaptoethanol, 26.3% glycerol, and 0.001%
Pyrinin Y). Lysates were boiled for 5 min prior to loading on sodium
dodecyl sulfate (SDS) polyacrylamide gels. Proteins were transferred to
nitrocellulose membranes and the membranes were blocked for 1 h in
5% Milk/TBST. Primary antibodies were diluted in 5% Milk/TBST and
incubated with the blot overnight at 4 °C. Horseradish peroxidase
(HRP)-conjugated secondary antibodies were diluted in 5% Milk/
TBST. Blots were processed with enhanced chemiluminescence and
densitometric quantiﬁcations were performed using ImageJ software.
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